Prestige Consumer Healthcare (PBH) is back in focus after quarterly earnings topped expectations, with revenue rising nearly 23% and earnings also coming in ahead of forecasts, supported by contributions from recent acquisitions. Even with the earnings beat, Prestige Consumer Healthcare’s share price has come under pressure, with the stock down 16.8% on a 1-day share price basis and weaker 7-day and 90-day share price returns, while the 1-year total shareholder return is also lower. This...
Prestige Consumer Healthcare Inc (PBH) beat sales and earnings expectations with revenue of $336.3 million, though Clear Eyes production volatility and a slight organic decline tempered the outlook.
(AP) — Prestige Consumer Healthcare Inc. (PBH) on Thursday reported fiscal second-quarter profit of $25.
TARRYTOWN, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2027 second quarter and first half earnings release on Thursday, November 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerh
Prestige Consumer (NYSE:PBH) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
Prestige Consumer Healthcare has seen its share price under pressure over the past year, and that kind of slide naturally puts the spotlight on what investors are paying for its earnings today. The question now is whether the current valuation of Prestige Consumer Healthcare's profit stream still makes sense given how the business is executing. The stock has fallen 24.2% over the past year, which raises the issue of whether the current earnings multiple properly reflects what the company is...
Prestige Consumer Healthcare (PBH) recently outlined medium term targets for fiscal 2027, putting fresh attention on its over the counter portfolio, free cash flow priorities, and the impact of Clear Eyes supply constraints. Prestige Consumer Healthcare’s recent medium term outlook lands after a tougher stretch in the market, with the share price down 23.34% year to date and the 1 year total shareholder return declining 24.25%, while the 30 day share price return has fallen 10.56%. This...
Prestige Consumer Healthcare (NYSE:PBH) said its strategy centers on investing in established over-the-counter brands, maintaining a high-margin operating model and using free cash flow for debt reduction, acquisitions and other shareholder-value initiatives. Speaking at a fireside chat, Chief Fina
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the followin
The voluntary recall of Clear Eyes Maximum Itchy Eye Relief affects 0.5-fluid-ounce bottles with the expiration date Sept. 30, 2027.
Detailed price information for Prestige Brand Holdings (PBH-N) from The Globe and Mail including charting and trades.
Nearly 40,000 bottles of Clear Eyes drops have been voluntarily pulled.
This is the newest page. Registered accounts read further back.